EVEREST MEDICINES Trademark

Trademark Overview

On Thursday, February 22, 2024, a trademark application was filed for EVEREST MEDICINES with the United States Patent and Trademark Office. The USPTO has given the EVEREST MEDICINES trademark a serial number of 98416690. The federal status of this trademark filing is REVIVED - AWAITING FURTHER ACTION as of Thursday, February 26, 2026. This trademark is owned by Everest Medicines (Singapore) Pte. Ltd.. The EVEREST MEDICINES trademark is filed in the Chemical Products category with the following description:

Active chemical ingredients for use in the manufacture of anti-cancer drugs; chemical additives for use in the manufacture of medicines; active chemical substances for use in the production of drugs for treating and preventing nephropathy, bacterial infection, cancer, gastrointestinal inflammation.
everest medicines

General Information

Serial Number98416690
Word MarkEVEREST MEDICINES
Filing DateThursday, February 22, 2024
Status616 - REVIVED - AWAITING FURTHER ACTION
Status DateThursday, February 26, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 17, 2024

Trademark Statements

NOT AVAILABLEMEDICINES
Goods and ServicesActive chemical ingredients for use in the manufacture of anti-cancer drugs; chemical additives for use in the manufacture of medicines; active chemical substances for use in the production of drugs for treating and preventing nephropathy, bacterial infection, cancer, gastrointestinal inflammation.

Classification Information

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateThursday, February 22, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEverest Medicines (Singapore) Pte. Ltd.
Party Type20 - Owner at Publication
Legal Entity Type24 - NOT AVAILABLE
AddressSingapore 049712
SG
Party NameEverest Medicines (Singapore) Pte. Ltd.
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressSingapore 049712
SG

Trademark Events

Event DateEvent Description
Thursday, February 22, 2024NEW APPLICATION ENTERED
Friday, June 28, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 11, 2024ASSIGNED TO EXAMINER
Wednesday, September 11, 2024NON-FINAL ACTION WRITTEN
Wednesday, September 11, 2024NON-FINAL ACTION E-MAILED
Wednesday, September 11, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 24, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 24, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 24, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 19, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 19, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 20, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 20, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 11, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 17, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 17, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 11, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, August 8, 2025SOU TEAS EXTENSION RECEIVED
Friday, August 8, 2025TEAS STATEMENT OF USE RECEIVED
Friday, February 13, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, August 8, 2025TEAS REQUEST TO DIVIDE RECEIVED
Friday, August 8, 2025DIVISIONAL REQUEST RECEIVED
Tuesday, February 24, 2026DIVISIONAL PROCESSING COMPLETE
Thursday, August 7, 2025SOU EXTENSION 1 FILED
Tuesday, February 24, 2026SOU EXTENSION 1 GRANTED
Tuesday, February 24, 2026CORRECTED NOA E-MAILED
Tuesday, February 24, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 26, 2026TEAS PETITION TO REVIVE RECEIVED
Thursday, February 26, 2026PETITION TO REVIVE-GRANTED
Thursday, February 26, 2026NOTICE OF REVIVAL - E-MAILED
Thursday, February 26, 2026SOU EXTENSION RECEIVED WITH TEAS PETITION

Related Keywords

medicines everest chemical active drugs cancer manufacture bacterial nephropathy inflammation infection preventing